A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies

NCT01416623 | Terminated Phase 1 DMC

• 1 other identifier: HNTN-I
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

Henatinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study is designed to evaluate the safety and tolerability of Henatinib in patients with Advanced Solid Malignancies

Conditions

Advanced Solid Cancer

Keywords

Advanced solid cancer; Henatinib; phase I

Outcome Measures

Primary Outcomes (1)

• The maximum-tolerated dose (MTD) regimen of henatinib will be defined as the maximum dose level at which no more than one subject out of six experiences a dose-limiting toxicity (DLT) after completing one treatment cycle.

  4 weeks

Secondary Outcomes (3)

• Number of participants with adverse events

  8 weeks

• Henatinib pharmacokinetic parameters may include AUC, Cmax, Tmax, and t1/2.

  4 weeks

• Objective response rate (ORR)

  8 weeks

Study Arms (1)

Henatinib

EXPERIMENTAL

Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily

Drug: henatinib

Interventions

henatinib DRUG

Henatinib Maleate Tablets

Henatinib

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically or cytologic (except sputum smear) confirmed metastatic or locally advanced solid tumor (At least one measurable lesion longest diameter ≥20 mm using conventional techniques or larger than 10 mm in diameter by spiral CT scan).
• Life expectancy of more than 12 weeks.
• Lack of standard treatment or standard treatment failure.
• Screening laboratory values within the following parameters:
• HB:≥90g/L
• ANC:≥1.5×109/L
• PLT:≥100×109/L
• ALT and AST:≤1.5×ULN(But if the liver metastases, ALT and AST:≤5×ULN) 1. Serum total bilirubin:≤1.5×ULN 2. Serum creatinine:≤1.5×ULN 3. Creatinie clearance rate:≥60ml/min 4. Electrolytes normal or return to normal after treatment
• Recovery from all clinically significant AEs related to prior therapies. Duration from the latest therapy is more than 6 weeks for nitroso or mitomycin, or more than 4 weeks for radiotherapy, chemotherapy, immunotherapy or other anti-cancer treatments (such as testing drugs, biologics, hormones or surgery).
• Signed and dated informed consent. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.

You may not qualify if:

• Evidence of CNS metastasis.
• Major surgery, open biopsy, or obvious trauma within 4 weeks before treatment.
• Obvious peritoneal implantation or pelvic obstruction.
• II level or above, peripheral neuropathy (NCI CTC AE v3.0).
• Known history of neurological or psychiatric disease.
• Suffering from high blood pressure and can not be reduced to the following range by monotherapy (systolic blood pressure \<140 mmHg, diastolic blood pressure \<90 mmHg).
• History of heart disease:\> NYHA II class congestive heart failure; unstable coronary artery disease (patients who had last myocardial infarction 12 months before can be enrolled), arrhythmias - requires antiarrhythmic drug therapy. Bazett's corrected QTc ≥ 480 ms or can not be measured. (Note: If ECG QTc interval ≥ 480 ms during the screening period, you must repeat 2 times, separated by at least 24 hours, the average QTc of the 3 times must be \<480 s, the patient can be enrolled in this study) .
• Coagulopathy (PT\> 16 s, APTT\> 43 s, TT\> 21 s, Fbg \<2 g / L), with a bleeding tendency or are receiving the therapy of thrombolysis or anticoagulation.
• Confirmed active gastrointestinal ulcers.
• Active severe infection (\> NCI-CTC 3.0 standard 2).
• Patients with severe epilepsy requires drug treatment (such as steroids or anti-epileptic drugs).
• Other serious illness or condition.
• Treated with VEGFR TKIs such as sunitinib or solafenib before study entry.
• Less than 4 weeks from the last clinical trial.
• Pregnancy, breast-feeding women or women of childbearing age without effective contraception.

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

Location

MeSH Terms

Interventions

2-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo(3,2-c)azepin-4-ketone

Study Officials

• jin Li, Dr

  Fudan University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 12, 2011
• First Posted: August 15, 2011
• Study Start: September 1, 2010
• Primary Completion: December 1, 2012
• Study Completion: December 1, 2012
• Last Updated: December 21, 2012

Record last verified: 2012-12

Locations

CN (1)